Vimarsana
Biggest News Aggregation in the World

Page 21 - Alacyclovir News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alacyclovir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alacyclovir Today - Breaking & Trending Today

Pfizer Stops Enrollment in Paxlovid Trial in Standard-Risk Population - Vimarsana News

Pfizer Stops Enrollment in Paxlovid Trial in Standard-Risk Population

Pfizer Inc said on Tuesday it would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after data analysis showed a non-significant reduction in hospitalizations and deaths.

US Doctors Reconsider Pfizer's Paxlovid for Lower-Risk COVID Patients - Vimarsana News

US Doctors Reconsider Pfizer's Paxlovid for Lower-Risk COVID Patients

Use of Pfizer's COVID-19 antiviral Paxlovid spiked last week, but some doctors are reconsidering the pills for lower-risk patients after a US public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.

EU in Talks for Common Purchase of Vaccine, Antiviral Against Monkeypox - Vimarsana News

EU in Talks for Common Purchase of Vaccine, Antiviral Against Monkeypox

The European Union is working on a common purchasing agreement for vaccines and antivirals against monkeypox, as cases of the viral disease usually endemic to Africa gather steam in Europe and beyond.

Focus on Antivirals, Vaccines as Monkeypox Continues - Vimarsana News

Focus on Antivirals, Vaccines as Monkeypox Continues

As monkeypox outbreaks continue around the globe, the focus has turned to medications and vaccines. Health officials have their eye on stockpiles of smallpox drugs, which can also be used for monkeypox.

CDC: Prescribe COVID Treatment Paxlovid Despite 'Rebound' Illness - Vimarsana News

CDC: Prescribe COVID Treatment Paxlovid Despite 'Rebound' Illness

The CDC recommends the oral drug for early-stage treatment of mild to moderate COVID-19 among people at high risk for progression to severe disease.